Clinical Scorecard: Berberine inhibits the growth of colorectal cancer organoids by interfering with cell cycle progression and decreasing lipid production
At a Glance
Category
Detail
Condition
Colorectal Cancer (CRC)
Key Mechanisms
Inhibits cell cycle progression and lipid metabolism
Target Population
Patients with colorectal cancer
Care Setting
Cancer research and treatment
Key Highlights
Berberine (BBR) significantly inhibits growth of CRC organoids.
BBR induces cell cycle arrest and increases ROS levels in organoids.
BBR disrupts lipid synthesis in colorectal cancer organoids.
BBR shows no harmful impact on healthy colonic tissues.
BBR may suppress malignant CRC phenotype through multiple mechanisms.
Guideline-Based Recommendations
Diagnosis
Utilize organoid models for studying CRC mechanisms.
Management
Consider BBR as a potential therapeutic agent for CRC.
Monitoring & Follow-up
Assess cell cycle progression and lipid metabolism in CRC treatment.
Risks
Monitor for potential side effects and tumor recurrence.
Patient & Prescribing Data
Patients diagnosed with colorectal cancer.
BBR is emerging as a natural compound with anti-cancer properties.
Clinical Best Practices
Incorporate phytomedicines like BBR in CRC treatment strategies.
Evaluate the efficacy of BBR in clinical settings for CRC management.
